Barbara Anne Swanson

USPTO Granted Patents = 26 (Patent Applications = 9)

CIPO Patents = 4 (Patent Applications = 9)

EPO Patents = 8 (Patent Applications = 7)

Average Co-Inventor Count = 4.2

ph-index = 6

Forward Citations = 174(Granted Patents)

Location History:

Encinatis, CA (US) (2018)
San Diego, CA (US) (2022)
Encinitas, CA (US) (2010 - 2024)

Company Filing History:

19 out of 112

Sorrento Therapeutics, Inc.

patents

7 out of 4,447

Eli Lilly and Company

patents

Years Active: 2010-2024

Loading Chart...

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11878058 - Antigen binding proteins that bind PD-L1 (2024-01-23),

2. 11242391 - Antigen binding proteins that bind PD-1 (2022-02-08),

3. 11155628 - Antigen binding proteins that bind c-Met (2021-10-26),

4. 11027012 - Antigen binding proteins that bind PD-L1 (2021-06-08),

5. 10696746 - Antigen binding proteins that bind CCR2 (2020-06-30),

6. 10668148 - Fully human anti-C-X-C chemokine receptor 3 (CXCR3) antibodies and methods of use thereof (2020-06-02),

7. 10584168 - Antigen binding proteins that bind PD-1 (2020-03-10),

8. 10479837 - Methods for treating subjects having a CXC chemokine receptor 5 (CXCR5)-responsive cancer by administering fully human anti-CXCR5 antibodies (2019-11-19),

9. 10435476 - Antibody therapeutics that bind JAG1 (2019-10-08),

10. 10377827 - Antigen binding proteins that bind c-met (2019-08-13),

11. 10058609 - Antigen binding proteins that bind PD-L1 (2018-08-28),

12. 10035855 - Antibody therapeutics that bind CD47 (2018-07-31),

13. 9951138 - Antigen binding proteins that bind CCR2 (2018-04-24),

14. 9944707 - Antibodies that bind epidermal growth factor receptor (EGFR) (2018-04-17),

15. 9765146 - Fully human anti-CXC chemokine receptor 5 (CXCR5) antibodies (2017-09-19),

Title: The Inventive Journey of Barbara Anne Swanson: Leading Innovations in Immunotherapy

Introduction: Barbara Anne Swanson, a prolific inventor hailing from Encinitas, CA, is a trailblazer in the field of biotechnology and immunotherapy. With an impressive portfolio of 26 patents, Swanson has significantly contributed to the development of cutting-edge antigen-binding proteins targeting PD-L1 and PD-1.

Latest Patents: Among her recent patents are groundbreaking inventions related to antigen-binding proteins that bind PD-L1 and PD-1. These patents encompass fully human antibodies, antibody fragments, derivatives, and polypeptides that specifically target PD-L1 and PD-1. The disclosed compositions and methods hold great promise in the treatment and diagnosis of PD-L1 and PD-1 related disorders, including inflammatory diseases and various types of cancer.

Career Highlights: Swanson's remarkable career includes notable stints at Sorrento Therapeutics, Inc. and Eli Lilly and Company. Her innovative work at these renowned companies has been instrumental in advancing the frontiers of immunotherapy and biopharmaceuticals. Swanson's dedication to pioneering research and development has earned her a reputation as a visionary in the field.

Collaborations: Throughout her career, Swanson has collaborated with esteemed professionals such as Heyue Zhou and John Dixon Gray. These talented individuals have been vital partners in Swanson's journey towards creating groundbreaking solutions in the realm of immunotherapy. Together, they have championed innovation and excellence in the scientific community.

Conclusion: Barbara Anne Swanson's contributions to the field of biotechnology and immunotherapy have been nothing short of extraordinary. Her inventive spirit, coupled with her relentless pursuit of scientific excellence, underscores her status as a leading figure in the realm of innovative medical technologies. Swanson's patents and collaborations stand as a testament to her unwavering commitment to advancing healthcare through cutting-edge research and development.

This text is generated by artificial intelligence and may not be accurate.